Novartis Stands by $5B Pluvicto Goal Despite EU Setback and Bispecific Competition on April 29, 2026 5B bispecific competition EU goal Novartis Pluvicto regulatory setback +
uniQure Faces Delay as FDA Walks Back Accelerated Approval for Huntington’s Gene Therapy on November 03, 2025 Accelerated AMT-130 Approved Clinical Trials gene therapy Huntington 's disease regulatory setback uniQure United States Food and Drug Administration +